
 **8th Annual Gastroenterology and Hepatology Symposium (2025) | 02/07/2025 7:35 AM St. John’s Resort**

The 8th Annual Gastroenterology and Hepatology Symposium will impart medical providers with a better understanding of the data available to treat both novel and common gastrointestinal disease in both current and novel ways. Case-based lectures, supported by data, research, and guideline-based approaches will be provided to ensure concepts are realized in a more patient-centered way. GI physicians and trainees, primary care providers, advanced practice providers, nurses will be informed of the novel therapies and diagnostics offered in the realms of inflammatory bowel disease (IBD), Hepatology, gastrointestinal motility, and therapeutic endoscopy.

**Program Goal**

1 Understand how to position medication treatment options for Inflammatory Bowel Disease

2 Understand how access to specialty care affects patient outcomes and how to improv care delivery

3 Understand the management of Inflammatory Bowel Disease in pregnancy

4 Review Best Practices in the ICU Care of End-Stage Liver Disease

5 Understand role of Liver Transplant and it's alternatives in the Care of Alcohol Related Liver Disease

6 Review updates in drug induced liver injury

7 Understand the diagnosis and management of small intestinal bacterial overgrowth

8 Review recent updates in Esophageal Motility

9 Understand the use, benefits and risks associated with GLP-1 medications

**Target Audience** Gastroenterology

**Faculty**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Sumit Singla, MD | Co-Director, Faculty | Consulting Fee-Boston Scientific - 09/23/2024 |
| Nirmal Kaur, MD | Faculty | Nothing to disclose - 12/04/2024 |
| Jason Schairer, MD | Co-Director, Faculty | Nothing to disclose - 10/09/2024 |
| Reena Salgia, MD, FAASLD | Co-Director, Faculty | Advisor-Eisai (Relationship has ended)|Advisor-Exelixis (Relationship has ended)|Advisor-Astrazeneca (Relationship has ended)|Advisor-Cook Medical (Relationship has ended) - 09/23/2024 |
| Jessica Jou, MD | Course Director, Faculty | Nothing to disclose - 11/03/2024 |
| Tobias Zuchelli, MD | Co-Director, Faculty | Consulting Fee-Boston Scientific - 09/11/2024 |
| Eva Alsheik, MD | Course Director, Faculty | Nothing to disclose - 04/08/2024 |
| Andrew Watson, MD | Faculty | Consulting Fee-Cook Medical - 10/09/2024 |
| Christina Miller, BS | CME Specialist | Nothing to disclose - 12/04/2024 |
| Faisal M Nimri, MD | Faculty | Nothing to disclose - 10/25/2024 |
| Robert Pompa, MD | Faculty | Nothing to disclose - 10/24/2024 |
| Stuart Gordon, MD | Faculty | Consulting Fee-Gilead Sciences, Inc. |Consulting Fee-CymaBay Pharmaceuticals|Consulting Fee-GlaxoSmithKline|Grant or research support-Gilead Sciences, Inc|Membership on Advisory Committees or Review Panels, Board Membership, etc.-National Institutes of Health|Grant or research support-CymaBay|Grant or research support-Viking Pharmaceuticals (Relationship has ended)|Grant or research support-Novartis (Relationship has ended)|Grant or research support-Intercept|Grant or research support-GlaxoSmithKline|Grant or research support-Mirum Pharmaceuticals |Grant or research support-Arbutus |Grant or research support-Pliant (Relationship has ended)|Grant or research support-COUR|Grant or research support-GlaxoSmithKline |Speakers Bureau-AbbVie - 11/03/2024 |
| Crystal M Gyiraszin, MS | CME Reviewer | Nothing to disclose - 02/20/2024 |
| Brian Ginnebaugh, MD | Faculty | Nothing to disclose - 10/04/2024 |
| William Davis, DO-Fellow | Faculty | Nothing to disclose - 11/03/2024 |
| Stephanie Betcher, MD | Faculty | Nothing to disclose - 11/04/2024 |
| Muhammad Zarrar Khan, MD-Fellow, Fellow Physician | Faculty | Nothing to disclose - 03/05/2024 |
| Iana Gueorguieva, MD, Senior Staff Physician | Faculty | Nothing to disclose - 03/05/2024 |
| Jessica Mellinger, MD | Faculty | Advisor-GlaxoSmithKline - 11/07/2024 |
| Faiza Bhatti, MD, Gastroenterologist | Faculty | Nothing to disclose - 11/04/2024 |
| Constantine J Karvellas, MD, FRCPC FCCM | Faculty | Consulting Fee-Grifols - 10/24/2024 |
| Arnold Wald, MD | Faculty | Nothing to disclose - 11/18/2024 |
| Andrew Y. Wang, MD, AGAF, FACG, FJGES, FASGE | Faculty | Other: I own publicly traded stock.-Pfizer|Other: I own publicly traded stock.-GE HealthCare Technologies - 11/20/2024 |

All of the relevant financial relationships listed for these individuals have been mitigated.

**ACCREDITATION STATEMENT:** Henry Ford Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**DESIGNATION STATEMENT:** Henry Ford Health designates this live course for a maximum of 7.25 *AMA PRA Category 1 Credit(s) TM*. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

ABIM MOC Part 2: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**FACULTY/PLANNING COMMITTEE DISCLOSURE STATEMENT:** In compliance with the ACCME standards for Commercial Support, all individuals in a position to control/influence the content of this activity are required to disclose relevant financial interests of their own with any ACCME defined commercial interests for the past 24 months and/or non-FDA approved use of a drug or a device that is included in the presentation. All relevant financial relationships have been mitigated prior to the commencement of the activity.

**ACCESSIBILITY STATEMENT:** Henry Ford Health provides qualified interpreters and other aids for Deaf, DeafBlind, and Hard-of-Hearing persons at no cost. To request assistance, contact the event coordinator Please allow a minimum of 3 days to process this request.